Systematic review of drug therapy for chorea in NXK2‐1‐related disorders: Efficacy and safety evidence from case studies and series
Authors:
- Laia Nou‐FontanetLNLaia Nou‐Fontanet
- Carmen Martín‐GómezCMCarmen Martín‐Gómez
- Anne‐Catherine Bachoud‐LéviABAnne‐Catherine Bachoud‐Lévi
- Giovanna ZorziGZGiovanna Zorzi
- Alessandro CapuanoACAlessandro Capuano
- NKX2‐1‐Related Disorders Guideline Working GroupNGNKX2‐1‐Related Disorders Guideline Working Group
- Juan Antonio Blasco‐AmaroJBJuan Antonio Blasco‐Amaro
- Juan Darío Ortigoza‐EscobarJOJuan Darío Ortigoza‐Escobar
Open Access
- 11 September 2023
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 30 (12) , 3928-3948
Abstract
Background: The NKX2‐1‐related disorders (NKX2‐1‐RD) is a rare disorder characterized by choreiform movements along with respiratory and endocrine abnormalities. The European Reference Network of Rare Neurological Disorders funded by the European Commission conducted a systematic review to assess drug treatment of chorea in NKX2‐1‐RD, aiming to provide clinical recommendations for its management.Methods: A systematic pairwise review using various databases, including MEDLINE, Embase, Cochrane, CINAHL, and PsycInfo, was conducted. The review included patients diagnosed with chorea and NKX2‐1‐RD genetic diagnosis, drug therapy as intervention, no comparator, and outcomes of chorea improvement and adverse events. The methodological quality of the studies was assessed, and the study protocol was registered in PROSPERO.Results: Of the 1417 studies examined, 28 studies met the selection criteria, consisting of 68 patients. The studies reported 22 different treatments for chorea, including carbidopa/levodopa, tetrabenazine, clonazepam, methylphenidate, carbamazepine, topiramate, trihexyphenidyl, haloperidol, propranolol, risperidone, and valproate. No clinical improvements were observed with carbidopa/levodopa, tetrabenazine, or clonazepam, and various adverse effects were reported. However, most patients treated with methylphenidate experienced improvements in chorea and reported only a few negative effects. The quality of evidence was determined to be low.Conclusions: The management of chorea in individuals with NKX2‐1‐RD presents significant heterogeneity and lack of clarity. While the available evidence suggests that methylphenidate may be effective in improving chorea symptoms, the findings should be interpreted with caution due to the limitations of the studies reviewed. Nonetheless, more rigorous and comprehensive studies are necessary to provide sufficient evidence for clinical recommendations.Keywords
This publication has 37 references indexed in Scilit:
- Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in theTITF1/NKX2-1geneJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Congenital Hypothyroidism with Neurological and Respiratory Alterations: A Case Detected Using a Variable Diagnostic Threshold for TshJournal of Clinical Research in Pediatric Endocrinology, 2011
- Brain-Lung-Thyroid DiseaseJournal of Child Neurology, 2011
- TITF-1 gene mutation in a case of sporadic non-progressive chorea. Response to levodopa treatmentBrain and Development, 2011
- PRISMA StatementEpidemiology, 2011
- Benign hereditary chorea: Clinical and neuroimaging features in an Italian familyMovement Disorders, 2010
- Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity DisorderJournal of Clinical Psychopharmacology, 2009
- “Jerky” dystonia in children: Spectrum of phenotypes and genetic testingMovement Disorders, 2008
- Clinical differentiation of genetically proven benign hereditary chorea and myoclonus‐dystoniaMovement Disorders, 2007
- New syndromic form of benign hereditary chorea is associated with a deletion of TITF‐1 and PAX‐9 contiguous genesMovement Disorders, 2006